How sulfa drugs work

Sulfa antibiotics work by mimicking PABA (para-aminobenzoic acid), a small molecule bacteria need to build folate. By occupying the active site of the bacterial enzyme dihydropteroate synthase, they block folate synthesis at its first step. Humans do not synthesise folate — we get it from food — so the pathway, and therefore the drug, is selective for bacteria.

The folate pathway, briefly

Bacteria, like all living cells, need folate to make DNA and certain amino acids. Unlike us, most bacteria cannot import folate efficiently from their environment; they synthesise it. The pathway begins with PABA, a small aromatic compound, which is joined to a pteridine fragment by the enzyme dihydropteroate synthase. The product is dihydropteroate, which is converted in two further steps to tetrahydrofolate, the active form.

Sulfa antibiotics resemble PABA closely enough to occupy the same enzyme pocket. The active site accepts the drug; the reaction does not proceed. Folate synthesis stalls. Bacterial growth slows or stops.

The structural reason is on the chemistry page: it is the arylamine on the sulfonamide ring that allows it to mimic PABA. Non-antibiotic sulfonamides — furosemide, HCTZ, celecoxib, the sulfonylureas — lack this group and do not interact with the folate pathway at all.

Why it doesn't poison us

Humans obtain folate from food: leafy greens, legumes, fortified cereals. We have no dihydropteroate synthase to inhibit. The drug therefore acts on the bacterial enzyme without an obvious human counterpart. This is the kind of selective toxicity that makes a useful antibiotic. The same logic underlies the safety of most older antibacterials.

That selectivity has limits. Sulfa drugs have side effects unrelated to the folate pathway — rashes, photosensitivity, marrow effects — and these are the basis of much of the clinical concern with the drug class. The side effects page covers them.

Trimethoprim and the synergy

The most prescribed sulfa drug is not a sulfonamide alone, but a fixed combination: sulfamethoxazole/trimethoprim, sold as Bactrim or Septra. Each component blocks a different step of folate metabolism: sulfamethoxazole blocks dihydropteroate synthase; trimethoprim blocks the next enzyme, dihydrofolate reductase. Together the two drugs cut the pathway twice.

The combination is more than additive. Where each drug alone is bacteriostatic — it stalls bacteria — the pair is bactericidal in many organisms. The synergy is the reason for the dual formulation, and one reason TMP-SMX has remained clinically important despite the rise of newer antibiotics.

Resistance

Bacteria evolve around drug pressure. Resistance to sulfonamides is widespread and well described. Mechanisms include altered dihydropteroate synthase enzymes that bind the drug poorly, increased PABA production, and acquisition of alternative folate synthesis genes on plasmids. Resistance is a major reason sulfa antibiotics are used for narrower indications today than in the 1940s, when they were the first effective antibacterials and the workhorse of treatment for streptococcal infection. The history page traces the arc.

Mechanism vs allergy

Mechanism and allergy are different questions and rest on different parts of the molecule. The drug's mechanism depends on the arylamine that mimics PABA. Most drug allergy to sulfa antibiotics is also linked, indirectly, to the arylamine — through reactive metabolites that bind to host proteins. This is why sulfa allergy is largely a phenomenon of antibiotic sulfonamides and only rarely of non-antibiotic ones. The distinction is the basis of the modern view on cross-reactivity.

Mechanism does not predict tolerance. Two patients with identical bacterial infections may tolerate the same drug very differently. Whether a particular person can take a sulfa antibiotic depends on their allergy history and on the prescriber's clinical judgement, not on the textbook mechanism alone.

Other sulfonamides, other mechanisms

The non-antibiotic sulfonamides each have their own target, unrelated to bacterial folate synthesis. Furosemide inhibits the Na⁺-K⁺-2Cl⁻ cotransporter in the thick ascending limb of the loop of Henle. HCTZ blocks the Na⁺-Cl⁻ cotransporter in the distal tubule. Sulfonylureas close ATP-sensitive potassium channels on pancreatic β-cells. Acetazolamide inhibits carbonic anhydrase. Celecoxib selectively blocks COX-2. The shared sulfonamide group is, in each case, just a piece of the binding site.